Wexford Online University Names Dr. Charles Foltz Professor with Focus on Science in Health and Fitness Field

Wexford Online University Names Dr. Charles Foltz Professor with Focus on Science in Health and Fitness Field

Dr. Charles Brown was recently named professor for Wexford University, where he will teach biochemistry, physiology and more with a focus on health and fitness. The 100 percent university offers a variety of health, exercise, sports and fitness degree programs of all levels to both U.S. and international students.

With a masters of Public Health in Epidemiology and doctorate in Interdisciplinary Molecular and Cellular Biology from Tulane University and a bachelors degree in Molecular Neuroscience from the University of California at Santa Barbara, Foltz is currently vice president of Research and Development at eHealth Screenings and senior project officer at Hip Hop Public Health. He is also the creator of 360 Cardio and has partnered with Polar heart rate monitors, the National Exercise and Sports Trainers Association (NESTA) and Total Health Interactive (THI). In addition, Foltz is a strength and conditioning coach and professional triathlon coach and manager. At Wexford University online, Foltz will teach subjects such as Biochemistry and Advanced Exercise Physiology with a focus on health and fitness for both local and international students.

Charles will offer Wexfords online students the perfect combination of science and real-world health and fitness experience and knowledge, said Jack Bauerle, Chancellor of Wexford University. He has worked with health and fitness organizations and individuals across the world, and were very pleased that hes bringing that wealth of wellness knowledge to Wexfords local and international students.

In addition, Foltz has earned certifications from the National Strength and Conditioning Association as a Certified Strength and Conditioning Coach and the National Academy of Sports Medicine as a Certified Performance Enhancement Specialist, a Certified Corrective Exercise Specialist and a Certified Personal Trainer.

Wexford University offers degree programs including an associate of arts degree in Fitness Training, a bachelor of science degree in Health and Fitness, a master of science degree in Nutrition and Exercise, a master of arts in Applied Sports Psychology and a doctorate degree in Applied Sports Psychology.

Wexford University is dedicated to providing world-class education through cutting-edge technology, offering direct application degree programs in an accelerated format with 100 percent online learning to save time and money. Programs include an associate of arts degree in Fitness Training, bachelors degree in Health and Fitness, masters degree in Nutrition and Exercise as well as masters degree and doctorate degree in Applied Sport Psychology. Wexford University is the higher education division of NESTA (National Exercise & Sports Trainers Association). For more information, please visit http://wexford.edu/.

See the original post:
Wexford Online University Names Dr. Charles Foltz Professor with Focus on Science in Health and Fitness Field

School prepares students for careers in medicine, tech

by Elizabeth Baier, Minnesota Public Radio

September 18, 2012

Audio player code:

ROCHESTER, Minn. Zakaria Mahamed wants to go to college and become a pediatrician, training he hopes will someday land him at the Mayo Clinic.

"When I see my family doctor, it makes me feel like I could be there one day," he said. "I could help these kids, I could find new cures for diseases, I can make a difference in my community."

But first, Mahamed has to make it through high school. The 11th grader thinks his chances of doing so are much better at the STEM Academy in Rochester, a charter school that aims to prepare immigrant and minority students for fields such as microbiology, nursing and engineering.

Inside the STEM Academy, teenage girls wear colorful hijabs on their heads and groups of boys speak Somali as they make their way to science, engineering and math classes. Nearly all of the 60 students are Somali-American.

Some are betting the school, in its second year, will help students who struggle in traditional schools find careers to build successful futures.

Mahamed is among them. Born in Rochester to Somali parents, he finished ninth grade at one of Rochester's traditional high schools before transferring to the math and science-focused school.

"When you're in a regular big school that doesn't have a small environment, everything is like you don't have enough time to talk and you'll never meet anybody," he said. "But here, you'll talk to everybody, you know everybody, everyone knows you, you know them."

Link:
School prepares students for careers in medicine, tech

Viruses not to blame for chronic fatigue syndrome after all

Public release date: 18-Sep-2012 [ | E-mail | Share ]

Contact: Jim Sliwa jsliwa@asmusa.org 202-942-9297 American Society for Microbiology

Contrary to previous findings, new research finds no link between chronic fatigue syndrome and the viruses XMRV (xenotropic murine leukemia virus-related virus) and pMLV (polytropic murine leukemia virus). A study to be published on September 18 in mBio, the online open-access journal of the American Society for Microbiology, reveals that research that reported patients with chronic fatigue syndrome carried these two viruses was wrong and that there is still no evidence for an infectious cause behind chronic fatigue syndrome.

"The bottom line is we found no evidence of infection with XMRV and pMLV. These results refute any correlation between these agents and disease," says Ian Lipkin of Columbia University, a co-author on the study.

Chronic fatigue syndrome (CFS), also known as myalgic encephalomyelitis (ME), is a disabling condition in which sufferers experience persistent and unexplained fatigue as well as any of a host of associated problems, including muscle weakness, pain, impaired memory, and disordered sleep. Medical treatment for CFS/ME costs as much as $7 billion every year in the U.S. alone.

The possible causes of CFS/ME have been argued and researched for years with no success. Results from separate studies in 2009 and 2010 that reported finding retroviruses in the blood of patients with CFS/ME created a sensation among patients and the medical community and offered hope that a tractable cause for this disease had finally been found. Since then, other investigators have been unable to replicate the results of those studies, casting doubt on the idea that these viruses, XMRV and pMLV, could be behind CFS/ME.

Lipkin says the National Institutes of Health wanted conclusive answers about the possible link. "We went ahead and set up a study to test this thing once and for all and determine whether we could find footprints of these viruses in people with chronic fatigue syndrome or in healthy controls," says Lipkin. The study in mBio puts the speculation to rest, he says. Scientists were wrong about a potential link between chronic fatigue syndrome and these viruses.

The study authors recruited almost 300 people, 147 patients with CFS/ME and 146 people without the syndrome, to participate. Researchers tested blood drawn from these subjects for the presence of genes specific to the viruses XMRV and pMLV, much in the way the earlier studies had done. But in this study, researchers took extraordinary care to eliminate contamination in the enzyme mixtures and chemicals used for testing, which may have been the source of viruses and genes detected in the earlier studies. XMRV and pMLV are commonly found in mice but there has never been a confirmed case of human infection with these viruses.

The authors of this study include many of the authors of the original papers that reported finding XMRV and pMLV in the blood of CFS/ME patients. This is an important point, says Lipkin, as their participation should lend credibility to the pre-eminence of these newer results over the flawed earlier studies, which offered a certain amount of false hope to the CFS/ME community.

Research on the causes of CFS/ME will continue, says Lipkin. "We've tested the XMRV/pMLV hypothesis and found it wanting," he says. But, he says, "we are not abandoning the patients. We are not abandoning the science. The controversy brought a new focus that will drive efforts to understand CFS/ME and lead to improvements in diagnosis, prevention and treatment of this syndrome."

Visit link:
Viruses not to blame for chronic fatigue syndrome after all

Anti-aging path is paved with new technologies

When Jill Reed ventured into the office of a local ophthalmologist and plastic surgeon a decade ago, it wasnt for cosmetic reasons. At the time, her anti-aging strategy amounted to facials and professional skincare products. But as the years passed, Reed, 65, of North Fulton, realized she was on a journey one that would gradually move her from facials to Botox to fillers.

I was a little shy in the beginning, Reed said. But as I experienced one procedure, it would give me the faith and encouragement to take another step should I need it.

She hasnt needed to take another step yet, but like many others in the baby boomer ranks, Reed will never say never. I think in todays times, you dont have to be as embarrassed about a lot of things you may have been 25 years ago, she said. If you have the money and you are able to make those decisions, go for it, girl! Or go for it, guy!

Increasingly, they are going for it. Nearly one-third of Georgians had moved into the 50 and up age bracket as of 2010, bringing with them new attitudes about aging. For some, aging well is best accomplished from the inside out. But others believe there is also nothing wrong with giving the ole tarpaulin a tweak.

The South Atlantic region made up of seven states, including Georgia has the highest percentage of cosmetic surgery practices in the country, according to data from the American Society for Aesthetic Plastic Surgery. Georgia ranks a distant second to Florida as the state with the largest number of board certified plastic surgeons.

In 2011, Americans spent nearly $10 billion on 9.2 million cosmetic procedures. Of those procedures, 82 percent were noninvasive, such as Botox and volumizing fillers, while 17 percent were surgical procedures, such as liposuction and face-lifts. Metro Atlanta doctors confirm the popularity of minimally invasive procedures as an alternative for patients who arent ready to embrace full-on surgery whether for economic or aesthetic reasons.

I can take five to six years off a face with fillers, said Dr. Jay Kulkin, founder of the Womens Institute for Health. Some people call it a liquid face lift.

The use of Botox (a muscle relaxer), volumizing fillers and collagen-stimulating lasers can rejuvenate aging skin of all types and temporarily mimic the effects of a face-lift, said Kulkin. Known for his extensive experience in laser technology, Kulkin believes one of the best noninvasive anti-aging therapies is CO2 fractional laser resurfacing. Tiny beams of heat penetrate the skins layers killing old skin cells and forcing the production of collagen, a primary component in skin elasticity.

Injectible dermal fillers, such as Sculptra, are also designed to stimulate collagen growth over a period of time, while other fillers, such as Juvederm or Restylane, give immediate results by filling out lines and wrinkles.

Dr. Tara Margarella, a cosmetic surgeon at Blue Med Spa in Midtown, uses fillers but in some cases prefers fat transfer to reduce the external signs of aging. Lines and hollowness around the eyes, nasolabial folds, thin lips, wrinkled skin and bony hands considered some of the most obvious signs of aging can all be reduced by taking fat from one part of the body and injecting it into the areas lacking volume. Fat, Margarella said, is easier to mold than fillers, particularly in delicate areas, such as under the eyes.

Read more here:
Anti-aging path is paved with new technologies

Research and Markets: Future Horizons in the US Microbiology Market: Supplier Shares and Sales Forecasts for 100 …

DUBLIN--(BUSINESS WIRE)--

Research and Markets (http://www.researchandmarkets.com/research/nngc8m/future_horizons) has announced the addition of the "Future Horizons in the US Microbiology Market: Supplier Shares and Sales Forecasts for 100 Infectious Disease Tests by Market Segment" report to their offering.

Highlights

- Comprehensive 1,037-page analysis of the US microbiology testing market.

- Major issues pertaining to the US microbiology laboratory practice, as well as key economic, regulatory, demographic, social and technological trends with significant market impact during the next ten years.

- Current scientific views on the definition, epidemiology, and etiology of major infectious diseases and microorganisms.

- Ten-year test volume and sales forecasts for nearly 80 microbiology tests performed in US hospitals, blood banks, physician offices, public health and commercial laboratories.

- Instrumentation technologies and feature comparison of leading analyzers.

- Sales and market shares of leading suppliers.

- Emerging diagnostic technologies and their potential market applications.

Visit link:
Research and Markets: Future Horizons in the US Microbiology Market: Supplier Shares and Sales Forecasts for 100 ...

ACLU challenges California DNA collection practice

SAN FRANCISCO An Alabama man was charged this month with the 1980 murder of an Oxnard teen. A Placerville man was arrested last month for a 1986 rape and murder of a San Mateo teen. A San Francisco man is currently on trial for the murder and robbery of a tourist two decades ago.

Technological advances in genetic research and computers in recent years have turned solving "cold cases" into near-routine police work. The California Attorney General reports that the state's DNA database of close to 2 million samples spits outs more than 425 "hits" a month, more than double the average monthly rate of 183 in 2008. More than 10,000 suspects have been identified in the last five years.

But on Wednesday, the American Civil Liberties Union will argue before a federal appellate court in San Francisco that California's DNA collection efforts have become unconstitutionally aggressive and that the spike in hits comes at the expense of civil liberties.

The ACLU is asking the 9th U.S. Circuit Court of Appeals to strike down California's Proposition 69, which authorized police to obtain a genetic sample from every person arrested on felony charges, not just those convicted. Some 25 other states have enacted similar laws since 62 percent of the California electorate passed the measure in 2004.

The issue of the warrantless swabbing of the cheek with a Q-tip of everyone arrested for a felony has sparked one of the hottest "search and seizure" debates in state and federal courts in decades.

The U.S. Supreme Court has already signaled its willingness to review Maryland's DNA collection law after a federal appeals court there ruled it unconstitutional in April. The California Supreme Court has agreed to review a lower court's overturning of the California law. Several other state and federal courts have already ruled or are weighing the issue throughout the country.

While the courts are sorting out the issue, California law enforcement officials are collecting more than 11,000 samples a month.

"Cold hit DNA is integral to bringing criminals to justice," said San Francisco District Attorney George Gascon, whose office is prosecuting William Payne for the 1983 strangulation murder of Nikolaus Crumbley. Crumbley's body was found in the city's McLaren Park along with DNA that was finally matched to Payne earlier this year. Payne denies killing Crumbley, saying his DNA was found at the scene because the two had had consensual sex. The match was made after Payne submitted a DNA sample after an unrelated assault conviction.

"Almost three decades later, we have charged the person responsible for this horrific murder," Gascon said.

The 9th Circuit itself has previously upheld the California law, which went into full effect in 2009. But underscoring the importance of the debate, a majority of the court's 24 judges voted to reconsider that divided ruling of three-judge panel. The matter now goes before a special "en banc" court of 11 judges.

Continued here:
ACLU challenges California DNA collection practice

Posted in DNA

Junk DNA, Junky PR

A week ago, a huge, painstakingly orchestrated PR campaign was timed to coincide with multiple publications of a long-term study by the ENCODE consortium in top-ranking journals. The ENCODE project (EP) is essentially the next stage after the Human Genome Project (HGP). The HGP sequenced all our DNA (actually a mixture of individual genomes); the EP is an attempt to define what all our DNA does by several circumstantial-evidence gathering and analysis techniques.

The EP results purportedly revolutionize our understanding of the genome by proving that DNA hitherto labeled junk is in fact functional and this knowledge will enable us to maintain individual wellbeing but also miraculously cure intractable diseases like cancer and diabetes.

Unlike the arsenic bacteria fiasco, the EP experiments were done carefully and thoroughly. The information unearthed and collated with this research is very useful, if only a foundation; as with the HGP, this cataloguing quest also contributed to development of techniques. What is way off are the claims, both proximal and distal.

A similar kind of theory of everything hype surrounded the HGP but in the case of the EP the hype has been ratcheted several fold, partly due to the increased capacity for rapid, saturating online dissemination. And science journalists who should know better (in Science, BBC, NY Times, The Guardian, Discover Magazine) made things worse by conflating junk, non-protein-coding and regulatory DNA.

Biologists particularly those of us involved in dissecting RNA regulation have known since the eighties that much of junk DNA has functions (to paraphrase Sydney Brenner, junk is not garbage). The EP results dont alter the current view of the genome, they just provide a basis for further investigation; their definition of functional is biochemically active two very different beasts; the functions (let alone any disease cures) will require exhaustive independent authentication of the EP batch results.

Additionally, the findings were embargoed for years to enable the PR blitz at minimum unseemly when public funds are involved. On the larger canvas, EP signals the increased siphoning of ever-scarcer funds into mega-projects that preempt imaginative, risky work. Last but not least, the PR phrasing choices put wind in the sails of creationists and intelligent design (ID) adherents, by implying that everything in the genome has a purpose under heaven.

What did the study actually do? The EP consortium labs systematically catalogued such things as DNAase I hypersensitive and methylated sites, transcription factor (TF) binding sites and transcribed regions in many cell types. Unmethylated nuclease-sensitive DNA is in the open configuration aka euchromatin, a state in which DNA can discharge its various roles. The TF sites mean little by themselves: to give you a sense of their predictive power, any synthetically made DNA stretch will contain several such sites. Whether they have a function depends on a whole slew of prerequisites. Ditto the transcripts, of which more anon.

Lets tackle junk DNA first, a term I find as ugly and misleading as the word slush for responses to open submission calls. Semantic baggage aside, the label junk was traditionally given to DNA segments with no apparent function. Back in the depths of time (well, circa 1970), all DNA that did not code for proteins or proximal regulatory elements (promoters and terminators) was tossed on the junk pile.

However, in the eighties the definition of functional DNA started shifting rapidly, though I suspect it will never reach the 80% used by the EP PR juggernaut. To show you how the definition has drifted, expanded, and had its meaning muddied as a term of art that is useful for everyone besides the workaday splicers et al who are abreast of trendy interpretations that may elude the laity, lets meander down the genome buffet table.

Protein-coding segments in the genome (called exons, which are interrupted by non-protein-coding segments called introns) account for about 2% of the total. That percentage increases a bit if non-protein-coding but clearly functional RNAs are factored in (structural RNAs: the U family, r- and tRNAs; regulatory miRNAs and their cousins).

Go here to read the rest:
Junk DNA, Junky PR

Posted in DNA

Calif. DNA Collection From Arrestees Challenged

An Alabama man was charged this month with the 1980 murder of an Oxnard teen. A Placerville man was arrested last month for a 1986 rape and murder of a San Mateo teen. A San Francisco man is currently on trial for the murder and robbery of a tourist two decades ago.

Technological advances in genetic research and computers in recent years have turned solving "cold cases" into near-routine police work. The California Attorney General reports that the state's DNA database of close to 2 million samples spits outs more than 425 "hits" a month, more than double the average monthly rate of 183 in 2008. More than 10,000 suspects have been identified in the last five years.

But on Wednesday, the American Civil Liberties Union will argue before a federal appellate court in San Francisco that California's DNA collection efforts have become unconstitutionally aggressive and that the spike in hits comes at the expense of civil liberties.

The ACLU is asking the 9th U.S. Circuit Court of Appeals to strike down California's Proposition 69, which authorized police to obtain a genetic sample from every person arrested on felony charges, not just those convicted. Some 25 other states have enacted similar laws since 62 percent of the California electorate passed the measure in 2004.

The issue of the warrantless swabbing of the cheek with a Q-tip of everyone arrested for a felony has sparked one of the hottest "search and seizure" debates in state and federal courts in decades.

The U.S. Supreme Court has already signaled its willingness to review Maryland's DNA collection law after a federal appeals court there ruled it unconstitutional in April. The California Supreme Court has agreed to review a lower court's overturning of the California law. Several other state and federal courts have already ruled or are weighing the issue throughout the country.

While the courts are sorting out the issue, California law enforcement officials are collecting more than 11,000 samples a month.

"Cold hit DNA is integral to bringing criminals to justice," said San Francisco District Attorney George Gascon, whose office is prosecuting William Payne for the 1983 strangulation murder of Nikolaus Crumbley. Crumbley's body was found in the city's McLaren Park along with DNA that was finally matched to Payne earlier this year. Payne denies killing Crumbley, saying his DNA was found at the scene because the two had had consensual sex. The match was made after Payne submitted a DNA sample after an unrelated assault conviction.

"Almost three decades later, we have charged the person responsible for this horrific murder," Gascon said.

The 9th Circuit itself has previously upheld the California law, which went into full effect in 2009. But underscoring the importance of the debate, a majority of the court's 24 judges voted to reconsider that divided ruling of three-judge panel. The matter now goes before a special "en banc" court of 11 judges.

Here is the original post:
Calif. DNA Collection From Arrestees Challenged

Posted in DNA

Applied DNA Sciences, Textile Centre of Excellence Unveil Textiles Anti-Counterfeiting Platform

STONY BROOK, NY--(Marketwire - Sep 17, 2012) - The Textile Center of Excellence at Huddersfield, United Kingdom (TCOE), and Applied DNA Sciences, Inc. ( OTCBB : APDN ) (Twitter: @APDN), a provider of DNA-based anti-counterfeiting technology and product authentication solutions, announced today the roll out of a new platform for protecting textile brands, under the SigNature DNA brand. The services, which the two organizations call "revolutionary," aim to protect textiles from a wave of counterfeiting which has struck the industry.

The platform includes applications which protect a wide range of textile, apparel and accessory products, including impregnation and authentication of DNA-marked:

The platform will be unveiled at the world-famous Premire Vision Pluriel, opening at Paris Nord Villepinte Parc d'Expositions (exhibition center) at Booth #5C18, from September 19-21, 2012. At the show, APDN and TCOE will feature demonstrations, samples, and technical experts, all showing the "unique, uncopyable, and uncompromising" abilities of the technology in protecting brands from counterfeiting.

In a joint statement, the two organizations said that their technology "offers our industry a unique and powerful means to mark and authenticate original items marked with DNA."

The two organizations described SigNature DNA as "a leading anti-counterfeiting technology that can be incorporated at any point in the textile supply chain as a means to link a genuine product to its original source of manufacture." Botanical SigNature DNA markers are authenticated in a laboratory and help to provide forensic evidence that can be used in a court of law.

The Textile Centre of Excellence has partnered with some of the most prestigious mills in the United Kingdom, including Bower Roebuck, Dormeuil, Holland and Sherry, Taylor and Lodge, and John Foster. Collectively, these fabric designers and weavers supply fabric to many of the most famous designer lines of Europe and America. Its botanical SigNature DNA-based technology protects historic and high-value Yorkshire Wool. APDN has separately partnered with Supima, a promotional organization of American growers of American Pima cotton.

Bill Macbeth, Managing Director of the Textile Centre of Excellence, commented: "SigNature DNA technology offers textile and clothing manufacturers a fool-proof and affordable solution to the growing menace of product counterfeiting. We are ready and willing to help brand owners and manufacturers to boost their brand values and revenues by incorporating this unique protection into their products."

Said Dr. James A Hayward, President and CEO, Applied DNA Sciences: "We believe that the Textile Centre's new platform is a powerful demonstration of the versatility and effectiveness of our SigNature DNA product. We urge visitors to Premiere Vision to visit the TCOE booth and see for themselves how DNA marking and authentication can add great value to their product lines."

About The Textile Centre of Excellence, and the Huddersfield and District Textile Training Company

The Huddersfield and District Textile Training Company was established in 1976 to unite the local textile industry in a shared approach to professional, equitable and high-quality training. In 1999 the company established the Textile Centre of Excellence, a 2 million development located in Leeds Road Huddersfield, providing a wide range of 'state of the art' textile and clothing research and development, training and production facilities including:

See the rest here:
Applied DNA Sciences, Textile Centre of Excellence Unveil Textiles Anti-Counterfeiting Platform

Posted in DNA

New gene could lead to better bug-resistant plants

ScienceDaily (Sep. 17, 2012) The discovery of a new gene could lead to better bug-resistant plants.

Research led by Michigan State University and appearing on the cover of this week's Proceedings of the National Academy of Sciences, demonstrates that domestic tomatoes could re-learn a thing or two from their wild cousins.

Long-term cultivation has led to tomato crops losing beneficial traits common to wild tomatoes. Anthony Schilmiller, MSU research assistant professor of biochemistry and molecular biology, was able to identify a gene that is involved in one of these beneficial traits.

Many tomato secrets are found in its hair. Trichomes, or hair-like protrusions, produce a mixture of specialized chemicals that shape the interactions between the plant and its environment. The location of the chemicals allows some of them to act as the first line of defense against pests.

One class of compounds, acyl sugars, is a frontline defender. Trichomes secrete acyl sugars to fend off pests. Schilmiller teamed with Robert Last, MSU professor of biochemistry and molecular biology, and Amanda Charbonneau, MSU doctoral researcher, to try to understand how these chemicals are made. Little was known about how acyl sugars were produced until now, and this research identifies and describes the first gene that participates in the production of the protective sugars in cultivated tomatoes, Schilmiller said.

"Acyl sugars play a critical role in allowing wild tomatoes to fend off bugs," he said. "Because cultivated tomatoes were not bred for their acyl sugar amounts and quality, they have reduced levels compared to wild ones we do not eat. Understanding how they are made is the first step toward breeding cultivated tomatoes, and other plants in this family, to make them more resistant to herbivores."

Other Solanaceous crops that could benefit from this research include potatoes, peppers, eggplants and petunias.

In addition, this work shows that the newly discovered gene is active only in one specific cell of one trichome type.

"Not only will we be able to potentially engineer heartier tomatoes, but understanding how to specifically target trichome gene expression without affecting the fruit, we'll also be able to add other important chemicals for insect resistance and possibly other beneficial traits to the surface of the plants," Schilmiller said.

The research was funded by the National Science Foundation.

Read the original post:
New gene could lead to better bug-resistant plants

Federal appeals court to hear challenge to California DNA collection law

SAN FRANCISCO -- On a March day three years ago in San Francisco's Civic Center Plaza, Elizabeth "Lily" Haskell was arrested during a rally against the Iraq war, cuffed on a felony allegation that she tried to spring another protester who had been taken into custody.

But once hauled off to jail, Haskell found herself in the legal crosshairs for more than just civic rabble-rousing. Sheriff's deputies ordered her to submit to DNA testing under a then-new provision of California law, giving her the choice of letting them swab the inside of her cheek or face an additional misdemeanor charge and sit in a jail cell for two days.

Haskell relented and took the DNA test. But now the Oakland woman is at the center of an American Civil Liberties Union legal challenge to a state law that allows law enforcement to collect DNA samples from anyone arrested for a felony, regardless of whether they are later charged or convicted. In Haskell's case, prosecutors never followed up the 2009 arrest with a criminal charge.

"My DNA was taken without any kind of due process," Haskell said last week. "I believe people should have the right to refuse to give their DNA."

On Wednesday, a special 11-judge panel of the 9th U.S. Circuit Court of Appeals will hear arguments in the latest round in the case, which has highlighted a legal issue that appears bound for the U.S. Supreme Court. In fact, in a brief order earlier this year, Chief Justice John Roberts said

At the request of civil liberties lawyers, the 9th Circuit agreed to take a second look at the Haskell case after a three-judge panel, in a 2-1 ruling, earlier this year upheld a voter-approved 2004 California law allowing DNA collection. The 9th Circuit rejected arguments that the law, which went into effect in 2009, tramples on the constitutional rights of those arrested for felonies, saying "government's compelling interests far outweigh arrestees' privacy concerns."

In court papers, lawyers for Haskell and others arrested but never charged with felonies argue that the California law "is an unprecedented expansion of the government's power to collect DNA evidence and to DNA profile individuals who have never been convicted of any crime."

To the ACLU, there is no reason someone's DNA should wind up in the state's DNA database if the person has never appeared in court, much less in front of a jury.

"People who haven't been convicted of anything shouldn't be treated like criminals," ACLU attorney Michael Risher said.

Law enforcement officials argue that the DNA collection law is a crucial tool in solving crimes. They liken taking a DNA swab at the time of arrest to fingerprinting.

More:
Federal appeals court to hear challenge to California DNA collection law

Posted in DNA

Lack of DNA database is a national disgrace

The Irish Times - Monday, September 17, 2012

MATTHEW HOLMES

LEGAL OPINION: This legislation will strengthen the ability of the Garda to detect and prevent crime and, in particular, to snare repeat offenders

A DNA DATABASE is one of the most effective crime-fighting tools ever devised. Thanks to DNA databases, crimes that were previously unsolvable are now being solved and miscarriages of justice are being corrected.

Such databases save valuable time in investigations by quickly eliminating suspects or pinning them to a crime scene. They are particularly effective in sex crimes and in catching repeat offenders such as burglars. They also have uses beyond the criminal sphere in terms of identifying bodies and helping to locate missing persons. In February 2000, the then government announced a plan to establish a DNA database in Ireland. More than a decade has passed and this has still not been done. The lack of relevant legislation is hampering criminal investigations.

To date, three Bills have been drafted which seek to establish a DNA database in Ireland the Criminal Justice (Forensic Sampling and Evidence) Bill 2007, the Criminal Justice (Forensic Evidence and DNA Database System) Bill 2010 and the Criminal Justice (Forensic Evidence and DNA Database System) Bill, currently before the Dil.

The first had to be dropped after the decision of the European Court of Human Rights in Marper v the United Kingdom, which led to European-level change in the law on DNA databases; the second lapsed following the change of government last year. In April 2011, Minister for Justice Alan Shatter told a conference of Garda sergeants and inspectors he hoped to publish a new Bill before the end of that year and to progress its speedy enactment. This was postponed to the middle of this year and it has been pushed back again to the end of the year.

There is currently an ad-hoc Irish DNA database which contains a representative sample of DNA profiles from 300 Irish citizens. To put this in context, the British database contained the profiles of 3.1 million people at the end of 2005. Clearly the scope for accuracy and effectiveness of results is exponentially higher in their system than in ours. In the UK, using the database has resulted in a 50 per cent hit rate. One in two samples on the databanks result in information regarding suspects being provided to the police. At one stage the hit rate was 74 per cent.

When he was in opposition, Mr Shatter said it was almost beyond belief that more than a decade had passed and this important legislation had still not been passed. Speaking in January 2011, he said: It is completely outrageous important issue hasnt been prioritised, and extraordinary lethargy has been displayed; the legislation is on the back burner. If there was any sense of urgency about it, this legislation would have been implemented last Easter considering it was published last January.

Over a year has passed since Mr Shatter became Minister for Justice, and legislation has yet to be enacted.

See more here:
Lack of DNA database is a national disgrace

Posted in DNA

Missing DNA evidence in Assange case

Forensic experts have failed to find crucial DNA evidence in the sexual assault case against Julian Assange, a British newspaper reports.

In a 100-page document shown to lawyers for the Australian WikiLeaks founder, Swedish police outlined their basis for seeking the 41-year-old's extradition to Stockholm to face questioning.

The report said staff at two forensic laboratories were unable to find conclusive evidence of Mr Assange's DNA on a torn condom provided by one of two women who claim to have been assaulted in August 2010.

However, the same analysts have found DNA believed to belong to Mr Assange on a condom provided by a second woman, The Mail on Sunday reported.

Mr Assange denies any wrongdoing and says sex with the two women was consensual.

He remains holed up in London's Ecuadorian embassy in a bid to avoid Swedish extradition, which he insists would lead to him being handed to authorities in the United States, where the actions of his secret-leaking website are under investigation.

The Swedish police report said that one woman, now aged 33, claims she was repeatedly molested by Mr Assange at her flat in Stockholm, adding on one occasion he deliberately broke a condom before wearing it to have unprotected sex with her against her will.

Scientists were unable to find traces of Mr Assange's DNA on the condom and his lawyers suggest that is because a fake one may have been submitted, the tabloid reports.

Mr Assange, who has been granted asylum by Ecuador, is yet to be formally charged with any offence by Swedish authorities.

View post:
Missing DNA evidence in Assange case

Posted in DNA

DNA evidence missing in Assange case

Forensic experts have failed to find crucial DNA evidence in the sexual assault case against Julian Assange, a British newspaper reports.

In a 100-page document shown to lawyers for the Australian WikiLeaks founder, Swedish police outlined their basis for seeking the 41-year-old's extradition to Stockholm to face questioning.

The report said staff at two forensic laboratories were unable to find conclusive evidence of Mr Assange's DNA on a torn condom provided by one of two women who claim to have been assaulted in August 2010.

However, the same analysts have found DNA believed to belong to Mr Assange on a condom provided by a second woman, The Mail on Sunday reported.

Mr Assange denies any wrongdoing and says sex with the two women was consensual.

He remains holed up in London's Ecuadorian embassy in a bid to avoid Swedish extradition, which he insists would lead to him being handed to authorities in the United States, where the actions of his secret-leaking website are under investigation.

The Swedish police report said that one woman, now aged 33, claims she was repeatedly molested by Mr Assange at her flat in Stockholm, adding on one occasion he deliberately broke a condom before wearing it to have unprotected sex with her against her will.

Scientists were unable to find traces of Mr Assange's DNA on the condom and his lawyers suggest that is because a fake one may have been submitted, the tabloid reports.

Mr Assange, who has been granted asylum by Ecuador, is yet to be formally charged with any offence by Swedish authorities.

Visit link:
DNA evidence missing in Assange case

Posted in DNA

DNA research key for Irish agriculture

The Irish Times - Monday, September 17, 2012

INNOVATION PROFILE:Teagascs Animal Bioscience facility, Grange, Co Meath

TEAGASCS NEWLY opened Animal Bioscience Facility in Grange, Co Meath, will use the latest DNA-based approaches to assist Irish farmers produce better quality and healthier livestock and ultimately improve Irish food production.

The publication of the genome sequence for cattle in 2009 has opened up the possibility to use these approaches to study commercially important traits. These include milk and meat production, immunity and disease, nutrition and reproduction, explains Teagasc director Prof Gerry Boyle.

The new facility was developed as part of the Teagasc vision programme which was initiated in 2006 with the objective of establishing centres of excellence in the key sciences that underpin Irish agriculture. Animal bioscience is a key component of the organisations Animal and Grassland, Research and Innovation Programme which integrates applied and strategic research across the main livestock species in Ireland namely dairy cattle, beef cattle and sheep.

The Animal and Bioscience Department carries out research in the areas of animal breeding and genomics, animal health and welfare, infection and disease, computational and systems biology, fertility and reproduction, feed efficiency and product quality. The new technologies being developed have the potential to accelerate the rate of gain in efficiency and quality.

Using the new areas of science such as genomics, proteomics, and systems biology, we are seeking to develop tools to more accurately identify the most profitable animals for current and future production systems, says Dr Richard Dewhurst, head of the Teagasc animal and bioscience department.

We are developing the optimal breeding programmes to maximise genetic gain in the long term. Our main research activities include the development of multi-breed genetic and genomic evaluations, breeding objectives and breeding programmes for dairy cattle, beef cattle and sheep. We also aim to identify genes, pathways and biological processes mediating resistance to infectious diseases in cattle and sheep and how these genes interact with pathogens and the environment.

While we are not quite at the stage of designer animals the use of these new DNA techniques could have a dramatic impact on Irish agriculture. If we take the DNA sequence of a bull, for example, we can use that to more accurately predict the characteristics that will be passed on to his progeny, Dewhurst explains. And the rate at which we can get the information is accelerating so we will soon be able to get the DNA sequence for individual animals. Its all about analysing the data and relating it to the traits we want to predict.

This highly scientific data led approach is a revolution in terms of the practices which obtained just 25 years ago. Over the past 25 years genetics has become much more statistics-based, before that it was an art, says Dewhurst. We have been using statistical models to predict traits in animals for the past while but now with the genome we will be able to identify good quality animals with the desired traits even before they reach maturity.

More:
DNA research key for Irish agriculture

Posted in DNA

Chemists develop reversible method of tagging proteins

ScienceDaily (Sep. 16, 2012) Chemists at UC San Diego have developed a method that for the first time provides scientists the ability to attach chemical probes onto proteins and subsequently remove them in a repeatable cycle.

Their achievement, detailed in a paper that appears online this week in the journal Nature Methods, will allow researchers to better understand the biochemistry of naturally formed proteins in order to create better antibiotics, anti-cancer drugs, biofuels, food crops and other natural products. It will also provide scientists with a new laboratory tool they can use to purify and track proteins in living cells.

The development was the culmination of a 10 year effort by researchers in the laboratory of Michael Burkart, a professor of chemistry and biochemistry, to establish a method to both attach a chemical probe at a specific location on a protein and selectively remove it. This flexibility allows researchers to study the protein with many different functional attachments, providing versatility akin to a biochemical Swiss Army knife. The great advantage of this technique is the broad flexibility of the attachments, which can be dyes, purification agents or mimics of natural metabolic products. Each of these attachments can be used for different purposes and biological studies.

Burkart's goal in his own laboratory is to understand more about the biochemical pathways of fatty acid metabolism and the biosynthesis of other natural products. One project focuses on engineering algae in order to produce improved biofuels. In this effort, the scientists hope to maximize the production of high quality algae oils, which could be used to supplement or supplant existing fossil fuels.

"In fatty acid metabolism, the fatty acids grow from an arm that eventually curls around and starts interacting with the metabolic protein," said Burkart, who is also associate director of the San Diego Center for Algae Biotechnology, or SD-CAB, a consortium of institutions in the San Diego region working together to make biofuels from algae commercially viable as transportation fuels. "What we wanted to know was how long does the growing fatty acid get before it starts binding with the protein?"

Burkart and chemists in his laboratory -- Nicolas Kosa, Robert Haushalter and Andrew Smith -- found a way to remove the chemical probe from this metabolic protein using an enzyme called a phosphodiesterase derived from the common bacterium Pseudomonas aeruginosa. Subsequent reattachment of a fatty acid analogue reconstituted the protein complex to its natural state. By repeating the process again and again, while examining the molecular changes in the fatty acid with nuclear magnetic spectroscopy, or NMR, during different metabolic stages, the scientists were able to detail the biochemical pathway of the fatty acid metabolism in a way they had never been able to do before.

"Without this tool, we would really have very limited ways of studying the dynamics of these fundamental metabolic processes," Burkart said. "This opened the door for us to finally examine in detail the fatty acid biosynthesis shared by algae, which you have to understand if you want to engineer ways to improve the quantity of oil that's made by algae or to make different types of oil molecules in algae that are better for biofuels."

The UC San Diego chemists also used NMR to verify that the process of chemically removing and attaching the chemical probes does not degrade or alter the protein in any way. "We've shown that we can do this iteratively, at least four or five times, without any degradation of the protein," said Burkart. "The protein remains very stable and can be studied very easily."

Because these same metabolic processes are shared by the metabolism of many natural products, including anti-cancer agents, antibiotics, and natural insecticides, Burkart said this new tool should have wide application in natural product chemistry labs.

"These are fundamental biochemical pathways that we still don't fully understand," he said. "We're now learning how these basic biosynthetic enzymes work. A large majority of drugs are derived from natural products and many future medicines can result from these pathways. There's a great interest now in synthetic biology, using these pathways to make new antibiotics or new anti-cancer drugs. They're all regulated by these same types of interactions."

Go here to read the rest:
Chemists develop reversible method of tagging proteins

How many times, if ever, have you googled a patient?

According to a WSJ blog post two years ago, it mentioned and asked, "By now, it’s well known that almost anyone you meet — from a potential employer to a prospective date — might be searching for information about you online. But would you feel strange knowing that your doctor was Googling you?" The blog post goes on to say "The practice appears to be widespread, according to an essay in the latest edition of the Harvard Review of Psychiatry, and it raises some thorny ethical questions for doctors, particularly those dealing with mental health." 

Some folks actually wrote a paper on this.  I happen to come across this news from KevinMD who made mention of this on his site in April of 2010 in a post entitled "Should doctors Google their patients?"

Point is, apparently I am not the first one to think of this, do it or subsequently write about it, but here is my response.

As a physician/pathologist there are a number of forms of data available to you, specimen requisition information, clinical history, electronic medical records, laboratory tests, radiology studies, operative notes, etc...


LetmegoogleyouIn some cases, the information may not be available (brunt of work-up, radiology, pre-operative visit, etc...) performed outside your institution where these impressions and results may normally be available to you.  The specimen requisition may simply state "change in bowel habits" or "liver mass" without much more than patient name, age, sex and a MRN of little value beyond appropriate patient ID.  No radiology, laboratories, physical examination findings, incomplete operative note and/or a clinician/surgeon who did not perform anything beyond the endoscopy or operation and does not recall by phone 2 or 3 days after the "case" anything about medication history, social history, radiology from outside hospital or post-operative course (assumingly these are all "negative", "non-contributory" or "not worth remembering".  When one calls for additional information the question is usually answered in the form of another question "Is it cancer?", "Is the margin negative?", or "How many lymph nodes are involved?"

A recent "liver tumor" submitted by a private physician at our hospital, where the work-up was largely done elsewhere, including pre-operative screening and imaging had an unusual histology.  No additional information was available.  A call to the surgeon about occupation, social history and medication history was met with one response "Is the margin negative?"  If I didn't tell him the patient's first name he would not have known that either. 


DnacredithistoryGoogle did.  And where he worked (irrelevant) what his "Likes" were, hobbies, interests and favorite TV shows.  The data I saw did not necessarily help to replace the normally present clinical data (assuming accurate when it is available), did not make the diagnosis less or more likely by itself, assuming the infomation online was accurate (i.e. did I have the right "John Doe") but it did help to substantiate the findings, albeit given circumstantial data.

As KevinMD and the WSJ blog notes and reader comments mention, there are many issues with this.   For some physicians apparently, using Google and the Internet to find publicly available information about their patients may shed some light into their diagnoses or management.  

One physician commented "I've done it, and it yielded invaluable info on a sick non-psych patient. Nailed the diagnosis."

What if there is something "out there" about an overtly litiginous patient?  Or one who smokes, is an admitted alcoholic, brags about excessive BMI, has started a blog on his/her personal battle with cancer, could any of these influence your diagnosis or approach after finding out?  

Perhaps in some cases and that is the point - shouldn't you know to help the patient and providers?

I have yet to meet a hepatologist who has not googled the name of a drug, prescription, over-the-counter or "other" health food store variety to look up any reports of hepatotoxicity or chemical compunds in those drugs that have been associated with hepatotoxicity.  

An old cardiologist (older now) told me as a first-year medical student, "Keith, there are two keys to practicing medicine; 1.  Do everything the same way, everytime.  This lowers the likelihood you will miss something. Whether it is a taking a clinical history, physical exam, reading an EKG, reading a chest x-ray (from outside in, or inside out, top-down, down-up), however you choose to do it, do it the same way everytime. And 2.  Cheat.  Cheat all the time.  Meaning get as much information as you possibly can.  MD stands for medical detective.  Get information from as many sources as possible.

This was shortly before Ask Jeeves or Yahoo!

I wonder what he would do if he had Google and an unresponsive patient, missing clinical information, radiology studies, unresponsive surgeon, forgetful clinician, etc...

Does this replace physician communication, documentation, the EMR, solid clinical business practices, actually talking to the patient, looking at his/her medical records, the slide(s) or X-rays?  Of course not.  May it yield information not mentioned and potentially useful? Ask Google.

 

 

 

 

 

 

 

Source:
http://feeds.feedburner.com/DigitalPathologyBlog

Can 2007 ASCO/CAP Scoring Guidelines for HER2 Protein Expression and Gene Amplification Be Applied to Gastroesophageal Adenocarcinoma?

Review of: Tafe, LJ, Janjiigian
YY, Zaidinski M, et al.  Human Epidermal
Growth Factor Receptor 2 Testing in Gastroesophageal Cancer Correlation Between
Immunohistochemistry and Fluorescence In Situ Hybridization
Arch Pathol Lab Med; 2011;135:1460-1465.


Nrgastroher2Experienced pathologists are
familiar with the bumpy and often controversial evolution of HER2/neu testing
in breast cancer patients. 

First, there was a breast
cancer drug trial employing a poorly designed trial assay followed by release
of the high demand drug Herceptin into a medical system without a remotely
adequate companion assay.  This was
followed by a confusing application of multiple anti-HER2 antibodies in no
standardized immunohistochemical assays interpreted by a range of pathologists
using different criteria all in parallel with a separate evolution of different
FISH assays. 

Before arriving at a reasonable
degree of standardization as outlined in the 2007 ASCO CAP guidelines, there
was a relatively prolonged period of sometimes heated consternation over which
assay was best, under what conditions, and using interpretive criteria.  And, during that period, we wrestled with a
lot of published laboratory correlation studies—the vast majority lacking any
clinical outcome data.  It’s not pleasant
to recall all of this controversy associated with HER2 testing in breast cancer
but hopefully it is a reminder of mistakes not to be repeated. 

We should remember these
lessons as we step into a new era of anti-HER2 therapies for gastroesophageal
and almost certainly other cancers from other primary sites.  The combination of Herceptin and chemotherapy
was very recently proven effective against HER2 positive advanced gastric and
gastroesophageal junction carcinomas in the TOGA clinical trial. 


Gastricher2Of great importance, the
standardized HER2 scoring systems used for breast cancer were not used in this
trial.  Instead, a body of preceding work
suggested that an alternative scoring system was needed for gastroesophageal cancers.  Basically, the traditional breast scoring
requirement for complete circumferential staining was modified to score
incomplete basal lateral membrane staining of gastric cancers as positive. 

In the trial,
immunohistochemistry was slightly more powerful than FISH in predicting drug
response with therapeutic responses in IHC 3+ tumors as well as IHC 2+ FISH
amplified tumors but not in FISH amplified tumors with lower
immunohistochemical scores 1 and 2. 

As a result, in Europe patients
with advanced gastroesophageal adenocarcinoma who are HER2 3 positive by
immunohistochemistry or IHC 2 positive with FISH amplification are eligible for
Herceptin therapy.  Slightly differently
in the United States, metastatic tumors that are IHC 3+ or HER2 amplified by FISH
are eligible. 

Some investigators have not
bought into the modified HER2 scoring system and hope to justify a more uniform
application of the existing breast cancer scoring system across different tumor
types.  Reporting in the November 2011
issue of Archives of Pathology and Laboratory Medicine [provide reference],
senior author Violetta Barbashina and co-authors measure concordance between
immunohistochemistry and FISH for evaluating HER2 status in gastroesophageal
carcinomas. 

Notably, in contrast to the
clinically validated scoring criteria for gastroesophageal carcinoma
established by the TOGA trial for Herceptin therapy, these authors deliberately
applied more traditional HER2 scoring criteria that are established for breast
cancer. 

They evaluated 135 paraffin
embedded advanced gastroesophageal carcinomas from the pathology files of
Memorial Sloan Kettering Cancer Center by HER2 automated immunohistochemistry
using PATHWAY Rabbit Monoclonal Antibody 4B5 on a Ventana BenchMark stainer
and, by HER2 FISH using the Path Vision dual probe procedure. 

Again, in this study, both ICH
and FISH were interpreted using criteria for breast cancer per the 2007 ASCO
CAP scoring guidelines.  By ASCO CAP
guidelines, 16 of 16 or 100% of the IHC 3+ tumors were FISH amplified; 16 of 20
or 80% of FISH amplified tumors were IHC 3+. 

Overall, IHC FISH concordance
was 97% for IHC 0 tumors, 93% for IHC 1+ tumors and 100% for IHC 3+ tumors—all
very high concordance rates—but note, that I have not described the FISH IHC
concordance rate for equivocal IHC 2+ tumors. 
Among this group of 8 equivocal IHC 2+ tumors, three were amplified,
four unamplified, and one equivocal indicating a roughly 50% concordance
rate. 

Finally, the authors
reclassified their IHC and FISH scoring using modified TOGA clinical trial criteria
and obtained a similar but no identical concordance rate.  From this, the authors conclude that HER2
testing in gastroesophageal cancers can be performed using 2007 ASCO CAP
scoring guidelines for breast cancer. 
Think about it.  I do not think
that such a bold conclusion is supported by this work. 

In their discussion, the
authors also state that for gastroesophageal cancers IHC 1+ and 2+ results should
be resolved by what they call definitive FISH testing.  Both this statement and the conclusion that
we can apply breast cancer scoring criteria are not supported by any clinical
evidence. 

In fact, the TOGA clinical
trial data contradict the notion that FISH results are in any way more
definitive or more predictive than IHC results. 
The TOGA clinical trial data actually suggests that for gastroesophageal
cancers, IHC results are more predictive of drug response. 

The authors have done a large
amount of work and report very good correlation between PATHWAY Ventana
immunohistochemistry HER2 testing and Path Vision FISH results in
gastroesophageal cancer but as far as I can tell that is all.  I have yet to see any clinical
evidence—certainly not in this paper—to support their suggestion that ASCO CAP
breast cancer scoring is acceptable or that FISH HER2 results are the
definitive answer for gastric cancers. 

I hope that this is not the
beginning of numerous laboratory correlation studies on HER2 testing on gastric
or other types of cancer that lack clinical outcome data but spawn speculative
conclusions about clinical utility.  One
suggestion I would make if it has not already been done is to retrospectively
score TOGA clinical trial gastroesophageal cancers by ASCO CAP breast cancer
criteria and see which system best predicted drug response. 

Short of that effort, someone
would have to essentially repeat the TOGA trial to truly answer the question
posed by these authors. 

To my knowledge and for now,
the modified TOGA scoring criteria for gastroesophageal cancer HER2 status
remain uniquely validated by a clinical trial. 

Biologically, it seems
imprudent to expect standards for HER2 testing in breast cancer to translate
simply and unchanged across primary and anatomic sites from breast to stomach
to lung or any other organ.  That is not
the case for anti-EGFR drug modality or laboratory testing algorithms in lung
and colon cancers which have benefited from quite different anti-EGFR drugs and
laboratory testing strategies.  In lung
cancer, use of anti- HER2 therapies is currently investigative but already
there is some published literature indicting that HER2 gene mutation status
(not protein over expression and not gene amplification) may identify the
subset of lung cancer patients who respond to Herceptin. 

The name of the game is predicting
drug response and that requires empirical clinical outcome data.

 

Source:
http://feeds.feedburner.com/DigitalPathologyBlog

Jerry and his Doctors

Every once in awhile I come across another physician blog that tells it like it is without ranting and raving about managed care/insurance issues, hospital administrators or patients with unmet expectations.

This one comes from an internal medicine resident recounting an experience with a terminally-ill patient and end-of-life decisions, a living will, the needs of patients and the decisions made by an attending physician and a resident physician.

Her experiences remined me of the 3 months I spent as an intern in critical care units.  The discussion, and perhaps, more importantly, enforcement/following of living wills and the battles that ensue with families, doctors, housestaff, attendings and medical technology in the war against human disease.

For a sobering account and one doctor's piece of mind on this check out:

The only thing I had to do was help Jerry and I failed


Doctors-band-aid-300x243

 

Source:
http://feeds.feedburner.com/DigitalPathologyBlog

Sept 11 — Remembering 11 years later

At around 8 PM, on September 10, 2001 I was on one of the last LaGuardia - Reagan Delta shuttles to leave New York City. I was returning from a trip to the laboratory at the hospital located on the U.S. Military Academy base in West Point, NY.  We had completed a successful AABB blood bank inspection and was returning home to Washington.  It was a trip I had done several times previously as the pathology consultant to Keller Army Community Hospital and would do several more times over the next four years on frequent site visits and to cover frozen sections as Keller did not have a full-time pathologist.  This experience was the nidus for telepathology in the Army.  I figured there had to be an easier way to cover remote frozens than to fly to New York City or drive for hours each way for 15 minutes of work.  

NikkormatFT2 IMGP1333 On this particular trip, leaving LaGuardia, I was able to capture a few images of lower Manhattan and New York harbor. At the time, I was still taking pictures with a film camera (and still do sometimes but it is getting harder to find quality film and processing facilities...). After takeoff I pulled out my old but trusty Nikkormat FT2 camera, snapped on my equally old but reliable 200mm lens and was able to get off 3 exposures. 

The lighting cooperated despite slow film and my telephoto lens.  I like the grainy nature, particularly for black and white photos.  I did not realize what I had on the roll until many months later and saw what are likely some of the last images of the World Trade Center, particularly from the air.  I could not find the original negatives but was able to scan some 4x6 prints I had made.  About 12 hours after I took this picture, the first plane hit the North tower of the World Trade Center. 

WTC1 WTC3

Source:
http://feeds.feedburner.com/DigitalPathologyBlog